Qorvo Biotechnologies said it is closing in on the launch of its point-of-care COVID-19 and influenza test as the firm works to expand its menu beyond COVID-19 and into syndromic panels and cardiac disease tests.
Companies that once rode high on the COVID-19 pandemic may now have to face the possibility of extinction in the coming years.
After two years of basking in the spotlight and money flowing into the industry as a result of the COVID-19 pandemic, financing for diagnostics companies has largely withered in 2022.
Outcome Capital’s Managing Director Paul Mieyal, Ph.D., CFA was interviewed by BioSpace for his views on the recent popularity of SPACs in the biotech space. The interview covers historical perspective, current market dynamics, and outlook for the next year.
COVID-19 brought significant attention and investment to the diagnostic industry. Coming out of the pandemic new pressures and challenges await. Director Craig Steger shares his views and insights on how firms must be strategic and agile in this new paradigm.
Managing Director’s Oded Ben-Joseph, PhD, and Paul Mieyal, PhD, were interviewed by 360Dx for their views on capital markets’ current receptiveness towards COVID diagnostics companies and the viability of SPAC’s for life sciences firms.
Navigating uncharted waters, biotech investors, executives and entrepreneurs are finding unique challenges (and opportunities) in a COVID-19 world. Contributing author, Outcome Capital’s Dr. Oded Ben-Joseph, Managing Director and Co-Founder of the Life Sciences Practice.
Partnerships and the move to value dominated the chatter at the BIO International Convention’s 25th annual partnering meeting on Monday in the life science hub of Boston.
Investors want to know: Will Big Pharma go bargain hunting, do a little M&A? Will it lift my biotech portfolio out of the gutter? Multiple factors are always at work. At the most basic level, pharma still needs to acquire new products to stay afloat. Little biotechs who create things need to be acquired, or go public, to reward their investors. Those facts never change. But there’s another powerful, and dark, force creating havoc in many biotech boardrooms. People who have witnessed it don’t like to talk about it. When they do, it’s in hushed tones…
Would you like to learn more about working with Outcome Capital or discuss your specific needs?